The federal government just launched a pilot program to help Medicare and Medicaid patients pay for hemp products like CBD, offering up to $500 in annual reimbursement. But a ban Congress passed could destroy it before patients ever benefit.
The timing is brutal. The Centers for Medicare and Medicaid Services began the reimbursement initiative partly to test whether hemp products could reduce overall healthcare costs. The program grants eligibility based on the 2018 Farm Bill definition of hemp: any cannabis plant containing less than 0.3% delta nine THC.
Then came the problem. A hemp ban tucked into Congress's spending bill will take effect November 12 and classifies any product with more than 0.4 milligrams of THC as federally illegal. That single change would criminalize most hemp products currently on the market, including the vast majority of CBD products people use.
"It would criminalize the vast, vast majority of hemp products, including most non-intoxicating CBD products," said Jonathan Miller of the US Hemp Roundtable.
Inesa Ponomariovaite, who runs a hemp company specializing in CBDA extract, recently visited Capitol Hill to warn lawmakers about the collision course they had set. The conversation revealed a knowledge gap she found alarming.
"Congress is trying to pass laws on something that they're not even fully understanding, and that's really going to affect us," Ponomariovaite said. She described having to explain the endocannabinoid system, a network of receptors in the brain and organs that interact with cannabinoids, to senators unfamiliar with the concept.
The endocannabinoid system regulates pain, memory, cognitive processing and energy, which explains why cannabis products work on the body the way they do. Ponomariovaite argues that hemp products with multiple cannabinoids produce stronger therapeutic results than isolated CBD alone, a nuance Congress appears to have missed in crafting the ban.
Attempts to defuse the situation have stalled. In December, Oregon Senator Ron Wyden reintroduced the Cannabinoid Safety and Regulation Act, which would scrap the ban in favor of FDA oversight ensuring products are safe and contaminant-free. Indiana Representative Jim Baird proposed a two-year delay in January. Neither has advanced.
Miller pointed to legislative dysfunction as the culprit. "Congress isn't passing anything these days, it's so polarized and so partisan that it's hard for them to pass even the most obvious bills, and so we're kind of caught up in that."
The White House has remained officially quiet but not silent. Trump posted on Truth Social calling on Congress to "update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on." The Trump administration has moved to reschedule cannabis to reflect medical value, though it has faced pushback on pro-cannabis moves, including the Medicare hemp pilot.
A coalition of groups including the Drug Free America Foundation sued Health Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz over the pilot, arguing the program promoted substances that could soon be illegal without proper regulatory procedure. The court rejected their bid to block it.
Ponomariovaite sees the entire debate as missing the real issue. Rather than splitting the plant into legal and illegal parts, lawmakers should focus on contamination. Hemp naturally absorbs toxins from soil, including metals, bacteria and mildew. When extracted for medicine, those contaminants concentrate in the final product.
A Forbes Health investigation recently found mold, yeast and fungicide in popular CBD products. While some companies like Ponomariovaite's conduct rigorous testing, quality controls remain uneven across the industry. Regulation like the Cannabinoid Safety Act could let the FDA step in.
Miller expressed cautious optimism that Congress might act before November. Ponomariovaite, facing the real possibility of the ban taking effect, said she would continue producing hemp products but would have to dramatically change her formula. "I basically have to do plant surgery," she said. "I am not a big fan of that. I want to keep all the chemistry in one bottle."
Author James Rodriguez: "Congress designed a pilot program to study hemp's cost benefits while simultaneously banning the products the program was meant to test. It's regulatory chaos masquerading as law."
Comments